2024
Fecal deoxycholic acid associates with diet, intestinal microbes and total bilirubin in primary sclerosing cholangitis
Chan C, Lemos M, Finnegan P, Gagnon W, Dean R, Yazdanafar M, Zepeda J, Vohl M, Trauner M, Korzenik J, Barbier O, Marco M, Bowlus C. Fecal deoxycholic acid associates with diet, intestinal microbes and total bilirubin in primary sclerosing cholangitis. JHEP Reports 2024, 101188. DOI: 10.1016/j.jhepr.2024.101188.Peer-Reviewed Original ResearchPrimary sclerosing cholangitisMarkers of BA synthesisFecal deoxycholic acidInflammatory bowel diseaseCholestatic liver diseaseFarnesoid X receptorFarnesoid X receptor activationSclerosing cholangitisDisease progressionFecal bile acidsTotal bilirubinDuct primary sclerosing cholangitisBile acidsLiver diseaseMarker of clinical outcomeBA synthesisChronic cholestatic liver diseaseRRNA gene sequencesUrsodeoxycholic acid useDeoxycholic acidAbundance of BlautiaMarkers of disease progressionVariable disease progressionAssociated with total bilirubinSerum total bilirubin
2023
Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis
Kremer A, Mayo M, Hirschfield G, Levy C, Bowlus C, Jones D, Johnson J, McWherter C, Choi Y. Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis. Hepatology 2023, 80: 27-37. PMID: 38117036, PMCID: PMC11191048, DOI: 10.1097/hep.0000000000000728.Peer-Reviewed Original ResearchAnti-pruritic effectsIL-31 levelsPrimary biliary cholangitisBile acid levelsIL-31PBC patientsBile acidsPruritus improvementBiliary cholangitisInterleukin-31Acid levelsIL-31 signalingSerum IL-31Pruritic skin diseaseDaily oral dosesSerum bile acidsNumerical rating scaleTotal bile acidsDose-dependent reductionPPAR-delta agonistOral dosesENHANCE studyPruritusHealthy volunteersPatients